Modulation of estrogen receptor-β isoforms by phytoestrogens in breast cancer cells

VERA CAPPELLETTI1, PATRIZIA MIODINI1, GIOVANNI DI FRONZO2 and MARIA GRAZIA DAIDONE1

1Department of Experimental Oncology, Unit #10, Istituto Nazionale per lo Studio e la Cura dei Tumori; 2Institute of Biomedical Technologies, CNR, Milano, Italy

Received November 11, 2005; Accepted December 29, 2005

Abstract. High consumption of phytoestrogen-rich food correlates with reduced incidence of breast cancer. However, the effect of phytoestrogens on growth of pre-existing breast tumors presents concerns when planning the use of phytoestrogens as chemoprevention strategy. Genistein, the active phytoestrogen in soy, displays weak estrogenic activity mediated by estrogen receptor (ER) with a preferential binding for the ER-β species. However, no information is at present available on the interaction between phytoestrogens and the various isoforms generated by alternative splicing. In two human breast cancer cell lines, T47D and BT20, which express variable levels of ER-β, the effect of genistein and quercetin was evaluated singly and in comparison with 17ß-estradiol, on mRNA expression of estrogen receptor-β (ER-β) isoforms evaluated by a triple primer RT-PCR assay. In T47D cells estradiol caused a 6-fold up-regulation of total ER-β, and modified the relative expression pattern of the various isoforms, up-regulating the ß2 and down-regulating the ß5 isoform. Genistein up-regulated ER-ß2 and ER-ß1 in T47D cells, and after treatment the ER-ß2 isoform became prevalent, while in BT20 cells it almost doubled the percent contribution of ER-ß1 and ER-ß2 to total ER-ß. Quercetin did not alter the total levels nor the percent distribution of ER-ß isoforms in either cell line. Genistein, through the modulation of ER-ß isoform RNA expression inhibited estrogen-promoted cell growth, without interfering on estrogen-regulated transcription. ER-ß and its ER-ß mRNA isoforms may be involved in a self-limiting mechanism of estrogenic stimulation promoted either by the natural hormone or by weaker estrogen agonists like genistein.

Introduction

Isoflavones, which are present in large amounts in soy beans, are able to protect against three major socially important diseases, i.e. cancer, coronary heart disease and menopausal symptoms (mainly osteoporosis) (1). Some concern about the potential ability of isoflavones to stimulate breast cancer growth in women has been raised by the observation that two-week dietary supplementation with soy increased pS2 levels in normal breast of premenopausal women (2). However, this is a typical estrogenic effect not necessarily linked to proliferation (3).

Among the isoflavones, genistein is considered as a selective estrogen receptor modulator and has therefore recently been proposed as a safe alternative to conventional hormone replacement therapy (1). Quercetin is contained in many edible fruits and vegetables (4) and exerts growth inhibitory activity on human breast cancer (5,6) as well as on other neoplasias.

While estrogens trigger the transcriptional activation and repression of both estrogen receptor isoforms, ER-α and ER-ß, genistein is almost exclusively ER-ß selective inasmuch as the relative binding affinity of ER-ß for genistein is 30-fold higher than that of ER-α (7); once bound, genistein selectively recruits co-regulators to ER-ß. Furthermore, the ER-ß-genistein complex induces a peculiar orientation in the AF-2 helix that is different from the ‘agonist position’ and very similar to the orientation induced by ER antagonists (8). Such conformation justifies the partial antagonist nature of genistein, explains its well-known protective effect (9), and indirectly sheds more light on the controversial biological role of ER-ß in the mammary gland, further supporting its function as a negative regulator of estrogenic action (10).

Although increasing evidence tends to link this receptor to the control of estrogenic over-stimulation, the function of ER-ß in normal and neoplastic breast tissue still remains obscure (11). Furthermore, various alternative splicing isoforms of ER-ß have been described in addition to the wild-type ER-ß (ER-B1): ER-B2, ER-B4 and ER-B5, all lacking exon 8 but sharing the 3'-end sequence with ER-B1 (12-14). ER-B2 (also called ER-ßc) appears to be particularly interesting because it shows significant dominant negative activity only against ER-α transactivation (13). The ER-B2 isoform differs from B1 in the replacement of exon 8 by a distinct sequence encoding for 26 amino acid residues and for in expression at higher mRNA levels in breast cancer compared to B1 (15,16).
It does not bind estradiol (13,17) and therefore does not directly activate ERE-controlled transcription; however, it interacts with ER-α in that it abolishes its transcriptional activity by impairing its DNA binding (13).

Alternative splicing is a major mechanism which generates diversity in the human transcriptome and its regulation is an important means of physiological control. Alternative splice data might have therefore the potential to substantially contribute to our understanding of biological processes involving ER-β (18).

In the present study we investigated the effect of the phyto-estrogens genistein and quercetin compared to 17β-estradiol on ER-α and ER-β mRNA expression in two breast cancer cell lines differing in hormone sensitivity and ER content. Our results showed the presence of a self-limiting mechanism of estrogen stimulation sustained by ER-β and particularly by its β2 isoform.

Materials and methods

Chemicals. Cell culture reagents were from Sigma (St. Louis, MO) and from BioWhittaker Europe (Vervier, BE); [32P]-dCTP was from the Radiochemical Center Amersham (Amersham, UK). Kits for transcription and PCR were from Roche (Roche Diagnostics, Mannheim, Germany) and Applied Biosystems (Foster City, CA), respectively. Genistein was purchased from Invitrogen (Milan, Italy) and quercetin was obtained from Aldrich (Steinheim, Germany). All other chemicals were of analytical grade.

Cell lines

Cell growth experiments. For cell growth experiments, T47D cells maintained in DMEM/F12, were seeded in T25 flask, allowed to attach for 24 h and passed to medium supplemented with 5% charcoal-stripped serum. Pre-treatment (hereafter referred as ‘cell priming’) with 5 μM genistein, 0.1 μM estradiol or vehicle alone, was carried at for 2 days in T25 flasks at a cell density of 38,000 cells/cm². Primed cells were collected by trypsin-EDTA treatment, counted and seeded in 6-well culture plates at a density of 104,000 cells/cm². Cell growth was assessed in medium supplemented with triplicate into 6-well culture plates at a density of 104,000 cells/cm². Pre-treatment (hereafter referred as ‘cell priming’) was adjusted for ß-actin expression and was amplified in parallel showing patterns of expression superposable to those of ß-actin. The mean densitometric data adjusted for ß-actin expression were recorded as percentages of the control.

Total RNA (1 μg) was reverse-transcribed using the commercially available first-strand cDNA synthesis kit for RT-PCR (AMV) (Roche Diagnostics) after incubation at 65°C for 15 min to remove secondary RNA structures according to the manufacturer’s instructions. The obtained cDNA was used for subsequent amplifications.

Determination of ER-α and ER-β isoform and pS2 mRNA expression. Amplification of ER-α cDNA was carried out in triplicate as previously described (19). The ubiquitously expressed β-actin gene was amplified in parallel. To exclude variations in β-actin expression induced by treatment (20), two additional housekeeping genes (S18 and GAPDH) were amplified in parallel showing patterns of expression superposable to those of β-actin. The mean densitometric data adjusted for β-actin expression were recorded as percentages of the control.

Semiquantitative determination of ER-β1 and its isoforms ER-β2 and ER-β5 was performed in triplicate by a triple-primer PCR using the following primers: ER-β1U, 5’-CGA TGC TTC TGT TTC TTG TGT-3’ sense located in exon 7 (1400-1420), GeneBank accession no. AB006590; ER-β1L, 5’-GCT CTC TTT GCT TTT ACT GTC-3’ antisense located in exon 8 (1667-1688), GeneBank accession no. AB006590; ER-β2L, 5’-CCT TAG GCC ACC GAG GTG TTG GGT GAT-3’ antisense located in ER-β2 alternative sequences, positions 1933-1913, GeneBank accession no. AF051428.

The PCR reaction was the same as the one used for ER-α with 4 ng/μl each of the 1U, 1L and 2L primers and 0.25 ng/μl each of the sense and antisense β-actin primers. The following amplification conditions were used for co-amplification of β-actin and ER-β isoforms: a single step of 10 min at 95°C to activate the enzyme, followed by 30 cycles of denaturation at 95°C for 30 sec, annealing at 60°C for 30 sec, elongation at 72°C for 1 min and a final single step at 72°C for 5 min.

Besides a 600-bp band corresponding to β-actin, the following products 295, 268 and 214 bp were obtained respectively corresponding to ER-53, ER-β1 and ER-β2 (21). The ER-β4, was not expressed in breast cancer.

The conditions for co-amplification were accurately determined with respect to the primer concentration in order to guarantee comparable amplification efficiencies between the highly expressed standard and the target gene expressed at lower levels. The linearity of the amplification reaction with respect to cycle number and cDNA amount was verified to allow semiquantitative estimates of the level of messengers.

Radioactive PCR products were separated on a 6% polyacrylamide gel under non-denaturing conditions. Gels were dried and the intensity of the radioactive signal was detected using a phosphorimager (Typhoon Scanner, Molecular Dynamics). The mean densitometric data for each single ER-β isoform were adjusted for β-actin expression and were recorded as percentages of the control. The relative percent-age of each isoform with respect to the sum of the signals (β1+β2+β5) was also calculated and used for correlative studies.

pS2 amplification was carried on with a non-radioactive protocol using the same master mix as described for ER-α and ER-β isoforms with a 1-μM concentration of following primers: pS2 sense, 5’-TTT GGA GCA AGG AGG CAA
TGG-3'; pS2 antisense, 5'-TGG TAT TAG GAT AGA AGC ACC AGG G-3'.

The following amplification conditions were used: a single 10 min step at 95˚C to activate the enzyme, followed by 31 cycles of denaturation at 94˚C for 45 sec, annealing at 64˚C for 45 sec, elongation at 72˚C for 55 sec and a final single step at 72˚C for 5 min. The amplification product was run on a 1% agarose gel in TAE buffer.

Data analysis. Data are presented as means ± SE of three independent experiments. Differences between ER expression in control and treated cells were tested by two-tailed Student's t-test. Results were considered significant at p<0.05 (22).

Results

T47D and BT20 cells represent hormone-sensitive and hormone-insensitive cell lines, respectively. As expected, this biological difference was reflected by a different ER-α profile (19), but also the ER-β expression was different. T47D cells expressed about 2.5-fold higher levels of total ER-β with respect to BT20 cells (data not shown). They also differed in terms of relative percentages of the ß1, ß2 and ß5 isoforms (Fig. 1). The prevalent isoform was ß2 in T47D cells (accounting for up to 50% of the total ER-ß) and ß5 (accounting for up to 84% of the total ER-ß signal) in BT20 cells.

Effects on ER-ß and its isoforms. Treatment with estradiol, genistein and quercetin triggered modifications in the total ER-ß levels as well as in the relative percentages of the isoforms. As no time dependency was observed overall, only results for the 48-h treatment are reported. A representative gel, reporting the effects of genistein treatment on ER-ß isoforms in both cell lines is shown in Fig. 1.

Effects of 17β-estradiol. Cells were treated with estradiol at concentrations ranging from 0.01 to 1 μM in medium supplemented with charcoal-stripped serum.

At the highest tested concentration, estradiol caused a more than 5-fold (p<0.01) up-regulation of total ER-ß in T47D cells, mainly due to the ER-ß2 and ER-ß1 isoforms, which increased 8- and 6-fold, respectively, compared to the control (p<0.05). By contrast, the ER-ß5 isoform was down-regulated by the treatment to about 50% of the control values (p<0.02). Consequently, the relative composition of the total ER-ß signal also underwent treatment-induced variations. ER-ß2, which was the main form in the untreated control cells, increased from 50% to about 80% after treatment with estradiol. Such effect did not appear to be dose-dependent (Fig. 2A). The percent increase of the ß2 form was compensated by a decrease in the relative ER-ß5 percentage from 32% to about 5%. The relative contribution of the wild-type ß1 to the total signal remained mostly unchanged upon estradiol treatment.

Estradiol treatment of the hormone-insensitive BT20 cells did not induce any significant variation in the total ER-ß mRNA levels (Fig. 2). None of the ER-ß isoforms underwent any significant change in expression levels and their relative contribution was not altered by the treatment.
Effects of genistein. T47D cells were treated with genistein at concentrations ranging from 5 to 30 μM (Fig. 3A). Treatment induced up-regulation of the total ER-ß levels which was more marked at the lowest concentration tested (385% of control, p<0.025) compared to the two highest concentrations (264% and 293% of control, respectively, p<0.02). A similar modulation pattern was observed for ER-ß2 and wild-type ß1, with approximately 4- and 5-fold up-regulation with respect to the control (p<0.025 and <0.05, respectively) at the 5 μM concentration. Conversely, the ß5 isoform was slightly but not significantly down-regulated (p<0.10) to about 60% and 77% of the control, respectively, in the presence of 5 or 15 μM and of 30 μM genistein.

The treatment also caused a change in the relative percent composition of the various isoforms. The ER-ß2 isoform, which represented 50% of the total ER-ß isoforms in the controls, accounted for 70% of the total after genistein treatment. The ER-ß5 isoform dropped from as much as 32% of the total ß signal to 5%-8%, regardless of the genistein concentration. The wild-type ER-ß1 isoform, which represented 19% of the total species, accounted for 27% after treatment with 5 μM genistein and 22% after treatment with 30 μM genistein.

In the BT20 cell line genistein did not significantly affect the total ER-ß expression profile, which was similar to the control at all tested concentrations (Fig. 3B). Similarly, the ß5 isoform was not modulated, while ß2, and to a lesser extent ß1, were up-regulated to 274% and 194% with respect to the control (p<0.005 and <0.02, respectively) in a dose-dependent fashion after treatment with 15 and 30 μM genistein. The relative percent contribution of the tested isoforms to the total ER-ß species was also affected by treatment. In the presence of 30 μM genistein the expression of ER-ß1 and ER-ß2 increased about 2-fold compared to untreated controls.

Effects of quercetin. T47D cells were treated with 1, 5, and 10 μM quercetin. There was a slight but not statistically significant increase in the total ER-ß levels (Fig. 4A), mainly due to the ER-ß2 isoform which was up-regulated to 152% (p<0.05) of the control, regardless of the dose.

The treatment also caused a change in the relative percent composition of the various isoforms. The ER-ß2 isoform, which represented 41% of the total ER-ß isoforms in the controls, accounted for 45% of the total after quercetin treatment. The ER-ß5 isoform dropped from as much as 31% of the total ß signal to 5%-8%, regardless of the quercetin concentration. The wild-type ER-ß1 isoform, which represented 13% of the total species, accounted for 11% after treatment with 10 μM quercetin.

In the BT20 cell line quercetin did not significantly affect the total ER-ß expression profile, which was similar to the control at all tested concentrations (Fig. 4B). Similarly, the ß5 isoform was not modulated, while ß2, and to a lesser extent ß1, were up-regulated to 274% and 194% with respect to the control (p<0.005 and <0.02, respectively) in a dose-dependent fashion after treatment with 15 and 30 μM genistein. The relative percent contribution of the tested isoforms to the total ER-ß species was also affected by treatment. In the presence of 30 μM genistein the expression of ER-ß1 and ER-ß2 increased about 2-fold compared to untreated controls.
relative ER-ß1 and ER-ß5 did not change after treatment with quercetin. In the BT20 cell line neither total ER-ß nor single isoform mRNA was significantly modified by the treatment (Fig. 4B).

Effects on ER-α. The effects on the mRNA expression of ER-α were not as dramatic as those on ER-ß. In Table I data are reported for 48-h treatments. It can be observed that, except for the lowest concentration tested, i.e. 0.01 μM, estradiol causes about 50% up-regulation with respect to control both in T47D and BT20 cells. Up-regulation of ER-α mRNA was observed with the two lower concentrations of genistein, but only in BT20 cells. Quercetin did not exert any effect in BT20 cells, while at the highest concentrations it slightly lowered ER-α in T47D cells.

Effects on cell growth. In order to evaluate the effect of ER-ß isoform modulation on subsequent estrogenic growth stimulation, T47D cells were pre-treated for 48 h respectively with 10^{-7} M 17ß-estradiol, 5 μM genistein or vehicle. Primed cells were collected, re-seeded in medium containing 10^{-8} M estradiol and grown for 6 days. Cells derived from triplicates were collected and counted. Data are shown in Fig. 5 as percentages of unprimed control. It clearly appears that priming with estradiol causes about 50% (149.4±11.6, p<0.001) potentiation of estrogenic stimulation, while priming with genistein potentiates the estrogenic stimulatory effect only by about 20% (120.3±9.1).

Effects on pS2. The pattern of induction of pS2 by estrogen was also evaluated in untreated cells and in cells primed respectively with vehicle, genistein and quercetin. Cells were primed for 48 h and thereafter treated with estradiol 10^{-8} and 10^{-11} M for 4 and 7 days.

Discussion

Estrogens, which are administered to many women to control adverse menopausal effects, increase the risk of breast cancer. Interestingly, the intake of plant-derived estrogens (phytoestrogens) has been found to be associated with a lower breast cancer incidence. Such paradoxical effects are not yet well understood at the molecular level and still many concerns exist about the use of phytoestrogens as safe hormone replacement therapy (23).

In a previous study in which we compared various effects of genistein and quercetin on estrogen receptor functions...
(growth stimulation/inhibition, nuclear translocation, expression of estrogen-regulated genes such as progesterone receptor, pS2 and cathepsin D), we observed that quercetin acts as a pure antiestrogen that does not bind the ER-α but prevents its interaction with the ERE, whereas genistein acts as a mixed estrogen-agonist/antagonist (3).

The partial estrogen antagonist nature of genistein could depend on its preferential binding to ER-β (7), which has been described as a negative regulator of estrogen-regulated transcription (10). In the present study we investigated further the paradoxical effects of genistein, which is protective against breast cancer risk, but still is a positive modulator of estrogen-regulated proteins like pS2 and cathepsin D (24) and compared it to quercetin. Our hypothesis was that genistein could act by selectively regulating ER-β and that up-regulation of ER-β could modify estrogen effects on hormone-sensitive cells. We therefore tried to link the data on ER-β isoform modulation to effects of estrogen on both growth and estrogen-regulated protein, i.e. pS2.

Various ER-β isoforms generated by alternative splicing have been reported in addition to the wild-type ER-β known as ER-β1. Among them ER-β2 (also called ER-βcx) was described as a potential inhibitor of estrogenic action (13). The β2 isoform neither binds estradiol nor forms complexes with the ERE. Microarray gene expression analysis has demonstrated that MCF-7 cells transfected with the β2 isoform display a different gene expression profile from the parental cell line and the one transfected with the β1 isofom (25). This would suggest a specific role for ER-β2, and ER-β isoforms in general, in addition to prompting further investigation into different models. We therefore set out to investigate whether genistein, quercetin and estradiol selectively regulate the expression of ER-β and its isoforms with respect to ER-α. Our aim was to gain insight into the mechanism of action of phytoestrogens and to better understand the role of the ER-β isoforms.

The modulation of ER mRNA levels was compared in typically hormone-sensitive (T47D) and hormone-independent cell lines (BT20) characterized by detectable or undetectable ER-α protein levels. ER messengers were, however, detectable, although at different levels in both cell lines.

Generally, the reported effects were much more striking in the case of ER-β and its isoforms compared to modulation of ER-α, independently of the ER expression pattern of the considered cell line.

Treatment with estradiol strongly increased total ER-β expression in hormone-sensitive T47D cells. The ER-β up-regulation was mainly due to an increase in the ER-β2 and wild-type ER-β1 isoforms and was not observed in the hormone-insensitive BT20 cell line. The enhanced expression of ER-β2, an ER-β isoform that does not bind estradiol and does not interact with DNA-responsive elements, is rather peculiar, especially if we consider its reported role as a regulator of ER-α activity. In fact, after treatment with the hormone, mRNA of the β2 isoform, which accounted for 50% of the total ER-β species mRNA, increased to about 80% of total ER-β. This result could be considered as an adaptation mechanism of the cell to continuous estrogenic stimulation. In keeping with this interpretation is the observation that ER-β2 mRNA was not modulated in the BT20 cell line. This cell line is hormone-insensitive and displays almost undetectable ER-α protein levels. Genistein, which in hormone-sensitive cell lines is estrogenic at low concentrations and antiestrogenic at higher concentrations, induced about 4-fold increase in total ER-β mRNA levels (5- and almost 6-fold in ER-β2 and ER-β1 levels, respectively) and a lesser increase (ranging between 2.6- and 4-fold) at higher concentrations. Also following treatment with genistein the relative percent distribution of the ER-β mRNA isoforms was modified, with an increase in the β2 and a decrease in the β5 isoform. However, in the case of genistein the modulations and the treatment-induced modifications were also seen in the hormone-insensitive BT20 cell line. This finding is not surprising inasmuch as the relative binding affinity of genistein for ER-β is about 30-fold higher than for ER-α. In BT20 cells, however, the modulation was different, since total ER-β mRNA levels were unaffected by genistein, while the β2 and to a lesser extent the β1 isoforms were up-regulated. In both cases the relative percent contribution to the total ER-β signal almost doubled.

Further support to these findings is also given by cell growth experiments carried out with estradiol in T47D cells. In this cell line pre-treatment with genistein inhibited cell growth following estradiol compared to pre-treatment with estradiol itself. It should however be noted that in both cases estradiol induced stimulation was stronger in estradiol and genistein pre-treated cells compared to vehicle pre-treated cells. This effect is probably due to the ER-α induction triggered by estradiol and genistein. While induction of ER-β affected estrogen-regulated cell growth, no effects were exerted on typically estrogen-induced transcripts like pS2. In fact pS2 was induced by estradiol with a similar pattern regardless of pre-treatment with either genistein or quercetin to differentially modulate ER-β.

On the contrary, quercetin, which has been demonstrated to exert an antiestrogenic effect, did not significantly modify ER levels, although in T47D cells a trend towards a slight (1.5-fold) increase in ER-β2 levels was observed.

It therefore appears that up-regulation of ER-β mRNA isoforms is a typical response to estrogenic stimulation and is consequently more marked in estrogen-responsive cells. The phytoestrogen genistein, which has a binding preference for the ER-β isoform, triggers up-regulation of ER-β both in T47D and BT20 cells, although to a lesser extent in the latter, and leads to an increase in the relative proportion of the negative regulator ER-β2.

We have already reported that up-regulation of ER-β levels may represent a kind of self-limiting effect of prolonged estrogenic stimulation, which is, however, observed not only with canonical estrogens but also with less active and weaker xenoestrogens (19). This study reinforces such hypothesis and adds a further layer of complexity as it appears that wild-type ER-β and its splicing isoforms are not regulated in the same way. This is in keeping with the emerging view that considers alternative splicing a major mechanism for expanding and regulating the repertoire of gene function (18).

Our results suggest that genistein through the modulation of ER-β isoforms, inhibits estrogen-promoted cell growth, but does not interfere with estrogen-regulated transcription.
This observation should help to clarify the present ambiguity about safety of phytoestrogens as chemoprevention or replacement therapy supporting their potential benefits.

Furthermore, our study confirms the observation that the wild-type ER-ß isoform is not the prevailing isoform in human breast tumors. In hormone-sensitive cells the prevailing ER-ß is the negative regulator ER-ß2, while in the hormone-insensitive cell line BT20 the prevailing isoform is the ER-ß5, whose role is not yet understood.

Acknowledgments

The present research was financially supported by grants from the Italian Association for Cancer Research (AIRC) and from the Italian Health Ministry.

References